APC
An Phu IrradiationBiotechnologyUPCOM
6.000
+11,11%
2026-10-19
Fundamental Analysis
63 / 100ARubric: Manufacturing
| Quarterly results | Relative Valuation | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Criterion | Latest Q EPS growth (YoY) | Avg EPS growth, last 3 (YoY) | Quarters with EPS growth | Revenue growth (YoY) | Gross margin change (pp, YoY) | Net margin change (pp, YoY) | Return on Equity (TTM) | Financial health (Debt/Equity) | Valuation (P/E vs 5-yr median) | Revenue (bn) | Rev YoY | NPAT (bn) | NPAT YoY | P/E | 5-Year Median P/E | P/E vs. 5-Year Median |
| Value | +63.8% | +15.7% | 2 / 3 | +11.6% | +5.50 pp | +15.47 pp | -3.9% | 0.29 | — | 32,2 | +11,6% | −2,4 | +63,8% | — | -7.23 | — |
| Pts | 12 | 0 | 8 | 4 | 12 | 12 | 0 | 12 | 8 | |||||||
Valuation annotation:Price: 6.000 (close price on 2026-10-19)EPS (TTM): −1.055,5
Financial charts
1.Revenue & growth
VND bn32,2Q2/26
1.Revenue & growth
VND bn32,2Q2/26
2.Profit & growth
VND bn-2,39Q2/26
3.Profit mix (Penman)
VND bn-21,0Q2/26
4.Margins & cost structure
%19.4%Q2/26
5.Returns & cash cycle
% · days-1.1%Q2/26
6.Earnings quality & cash
VND bn49,4Q2/26
7.Asset structure
VND bn721Q2/26
8.Funding & debt health
VND bn · times721Q2/26
9.Revenue backlog
VND bn0,11Q2/26
10.Valuation
times · %-5,2×Q2/26
11.EPS growth & dilution warning (CANSLIM)
VND per share; growth in %-119Q2/26
Adjusted EPS growth, latest quarter
No comparable quarter a year earlier
Average adjusted EPS growth, 3 quarters
No comparable quarter a year earlier
Quarters at 25%+ growth
0/3
Share dilution rate, 1 year
0.0%
Source: vnstockData through Q2/26